扫 描 看 全 文
龙美春，Email: firstname.lastname@example.org, ORCID: 0000-0002-5541-2884
郭勤，Email: email@example.com, ORCID: 0000-0001-5785-8372
龙美春, 张敏, 姚玲娜, 等. 44例小肠克罗恩病的临床特征[J]. 中南大学学报(医学版), 2021,46(10):1109-1113.
Meichun LONG, Min ZHANG, Lingna YAO, et al. Clinical features of 44 patients with small bowel Crohn’s disease[J]. Journal of Central South University. Medical Science, 2021,46(10):1109-1113.
龙美春, 张敏, 姚玲娜, 等. 44例小肠克罗恩病的临床特征[J]. 中南大学学报(医学版), 2021,46(10):1109-1113. DOI： 10.11817/j.issn.1672-7347.2021.190732.
Meichun LONG, Min ZHANG, Lingna YAO, et al. Clinical features of 44 patients with small bowel Crohn’s disease[J]. Journal of Central South University. Medical Science, 2021,46(10):1109-1113. DOI： 10.11817/j.issn.1672-7347.2021.190732.
Objective,2,At present, there are many studies on Crohn’s disease of terminal ileum and colon, but few studies on Crohn’s disease of small intestine alone. This study aims to analyze the clinical features and therapeutic effect of small bowel in adult patients with Crohn’s disease so as to strengthen the diagnosis and treatment for this disease.,Methods,2,From July 1, 2015 to October 31, 2018, patients with small bowel Crohn’s disease at Department of Gastroenterology, Third Xiangya Hospital of Central South University, were enrolled. At the same time, patients' demographics and clinical data were collected.,Results,2,A total of 44 patients were small bowel Crohn's disease. Among them, 40 patients were male. The age at diagnosis was (35.8±10.3) years old and disease duration was (35.2±59.5) months. The subtypes included 29(65.9%) of ileum, 7(15.9%) of jejunum, 8(18.2%) of ileum with jejunum. There were 27(61.4%) of stricture behavior, 4(9.1%) of penetrating behavior, and 13(29.5%) of non-stricture and non-penetrating behavior. Endoscopic visible stricture (29/85, 34.1%) was common, followed by longitudinal ulcers (27/85, 31.8%). Non-caseate granulomatous were found in 2 cases (4.5%). The score of Crohn’s disease activity index was correlated to hemoglobin, hematocrit, and erythrocyte sedimentation rate (all ,P,<,0.05). Among the most common symptom of abdominal pain (34/44, 77.3%), 11 patients (25.0%) developed complications (eg. intestinal obstruction) during the follow-up, and 66.7% of patients treated with mesalazine had complications.,Conclusion,2,Patients with ileum account for a large proportion in patients with small bowel Crohn’s disease. Stricture is more common in small bowel Crohn’s disease. Stricture and longitudinal ulcer are more common under enteroscopy. Crohn’s disease activity index is correlated to hemoglobin, red blood cell specific volume, and erythrocyte sedimentation rate. The most common complication is intestinal obstruction. Mesalazine is less effective on small bowel Crohn’s disease.
small bowelCrohn’s diseaseclinical features
Gajendran M, Loganathan P, Catinella AP, et al. A comprehensive review and update on Crohn’s disease[J]. Dis Mon, 2018, 64(2): 20-57.
吴开春, 梁洁, 冉志华, 等. 炎症性肠病诊断与治疗的共识意见(2018年·北京)[J]. 中国实用内科杂志, 2018, 38(9): 796-813.
WU Kaichun, LIANG Jie, RAN Zhihua, et al. The consensus on diagnosis and management of inflammatory bowel disease (2018·Beijing)[J]. Chinese Journal of Practical Internal Medicine, 2018, 38(9): 796-813.
Cui GL, Yuan A. A systematic review of epidemiology and risk factors associated with Chinese inflammatory bowel disease[J]. Front Med (Lausanne), 2018, 5: 183.
Chan WPW, Mourad F, Leong RW. Crohn’s disease associated strictures[J]. J Gastroenterol Hepatol, 2018, 33(5): 998-1008.
Kim OZ, Han DS, Park CH, et al. The clinical characteristics and prognosis of Crohn’s disease in Korean patients showing proximal small bowel involvement: results from the CONNECT study[J]. Gut Liver, 2018, 12(1): 67-72.
Thia KT, JrLoftus EV, Sandborn WJ, et al. An update on the epidemiology of inflammatory bowel disease in Asia[J]. Am J Gastroenterol, 2008, 103(12): 3167-3182.
Hu PJ. Inflammatory bowel disease in Asia: the challenges and opportunities[J]. Intest Res, 2015, 13(3): 188-190.
Kopylov U, Yung DE, Engel T, et al. Fecal calprotectin for the prediction of small-bowel Crohn’s disease by capsule endoscopy: a systematic review and meta-analysis[J]. Eur J Gastroenterol Hepatol, 2016, 28(10): 1137-1144.
Stawczyk-Eder K, Eder P, Lykowska-Szuber L, et al. Is faecal calprotectin equally useful in all Crohn’s disease locations? A prospective, comparative study[J]. Arch Med Sci, 2015, 11(2): 353-361.
Gauss A, Geiss T, Hinz U, et al. Quality of life is related to fecal calprotectin concentrations in colonic crohn disease and ulcerative colitis, but not in ilealcrohn disease[J]. Medicine (Baltimore), 2016, 95(16): e3477.
Yang L, Ge ZZ, Gao YJ, et al. Assessment of capsule endoscopy scoring index, clinical disease activity, and C-reactive protein in small bowel Crohn’s disease[J]. J Gastroenterol Hepatol, 2013, 28(5): 829-833.
Mitselos IV, Katsanos KH, Tatsioni A, et al. Association of clinical and inflammatory markers with small bowel capsule endoscopy findings in Crohn’s disease[J]. Eur J Gastroenterol Hepatol, 2018, 30(8): 861-867.
Ooi CJ, Makharia GK, Hilmi I, et al. Asia Pacific Consensus Statements on Crohn’s disease. Part 1: Definition, diagnosis, and epidemiology[J]. J Gastroenterol Hepatol, 2016, 31(1): 45-55.
Lim WC, Hanauer S. Aminosalicylates for induction of remission or response in Crohn’s disease[J]. Cochrane Database Syst Rev, 2010(12): CD008870.
Akobeng AK, Gardener E. Oral 5-aminosalicylic acid for maintenance of medically-induced remission in Crohn’s Disease[J]. Cochrane Database Syst Rev, 2005(1): CD003715.
Fasanmade AA, Adedokun OJ, Olson A, et al. Serum albumin concentration: a predictive factor of infliximab pharmacokinetics and clinical response in patients with ulcerative colitis[J]. Int J Clin Pharmacol Ther, 2010, 48(5): 297-308.